Orphan Drugs Market – 2020 Application Scope, Types, Technology Benefits and Global Business Outlook By Coherent Market Insights

In pharmaceutical industry, an orphan drug is an agent developed to treat medical conditions, which would not be profitable to produce without government assistance since the disease is extremely rate. Rare diseases such as Tourette syndrome, Huntington’s disease, muscular dystrophy, myoclonus, and ALS (Lou Gehrig’s disease) are some of those diseases for treatment, of which adequate drugs have not been developed, and hence these diseases are treated by orphan drugs. Orphan drugs are developed by pharmaceutical companies for public health need, whose sale is very minimal as the market for the drug is too slim compared to normal drugs. Around 6-8% of global population use orphan drugs. Moreover, symptoms of orphan diseases may appear at birth or typically in childhood, which includes cystic fibrosis, infantile spinal muscular atrophy, familial adenomatous polyposis (FAP), and some others.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/500

Market Drivers

Developing novel indications for designated orphan drugs is expected to drive the orphan drugs market

Around 5,000 rare diseases are listed globally, of which 80% are listed as genetic origins.  Moreover, adults are 50% more likely to get infected with these diseases. Increasing need for the development of orphan drugs, which will treat such diseases coupled with initiatives taken by government organizations is expected to drive growth of the global orphan drugs market during the forecast period.  For instance, the U.S. Food and Drug Administration (FDA) is providing incentives to pharmaceutical and biotechnology industries, in order to enhance their research and development in orphan drugs. Furthermore, there are few drugs that have been withdrawn from the market due to certain risk developed over prolong administration of these drugs. However, these drugs have shown good results for treatment of those diseases, in which particular do not have any standard drug, which is expected to drive the market growth in the near future. For instance, thalidomide used as a hypnotic drug was withdrawn from market when teratogenic risk was discovered, however, this drug has shown prominent result in treating leprosy.

Market Restraints

Slim profit margin for manufacturers and short timeline product development are expected to restrain the global orphan drugs market growth over the forecast period.  However, manufacturers can focus on untapped emerging market, which is expected to create lucrative growth opportunities in the global orphan drugs market.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/500

Increasing prevalence of rare cancer in patients owing to oncological diseases segment to dominate in the global orphan drugs market

The global orphan drugs market is segmented on the basis of disease, by product type and by region

On the basis of disease type,

• Hematologic and Immunologic diseases
• Infectious diseases
• Metabolic diseases
• Neurologic diseases
• Oncologic diseases
• Other orphan diseases

On the basis of product type,

• Biological orphan drugs
• Non-biological orphan drugs

Numerous collaborative research programs across North America and Europe is owing to growth of orphan drugs market

Regional segmentation of orphan drugs market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America holds dominant positions in the global orphan drugs market. This dominance is attributed to robust regulatory and reimbursement framework and incentives given by the U.S. Food and Drug Administration (FDA) for research and development in orphan drugs sector. Key players in the Europe and North America are focused on collaborative strategies to provide research data on rare diseases to manufacturers, patients, and health experts, which gives timely medical care, thus boost the orphan drug market. Moreover, growing population and increasing prevalence of genetic diseases is expected to drive growth of Asia Pacific orphan drugs market during the forecast period.

Initiatives taken by government to increase the investment in orphan drugs development driving the growth of orphan drugs market.

Increasing investments and proactive initiatives taken by government is assisting orphan drug manufacturers. For instance, the U.S. government provides 50% of tax credit on the research and development expenses spent on the orphan drugs development by manufacturers. However the high cost of the orphan drugs and generation of small sales from it is amongst those factors which is lowering the interest of companies for market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/orphan-drugs-market-500

Key players operating the global orphan drugs market are Acorda Therapeutics, Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter international, Bayer Healthcare Pharmaceuticals, Biomarin Pharmaceuticals, Novartis, F.Hoffmann-La Roche AG, and Johnson and Johnson.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837